Juan Francisco Merino-Torres

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Matthias von Herrath, Stephen C. Bain, Bruce W. Bode et al. · The Lancet Diabetes & Endocrinology · 2021 · 163 citations · Full text

Inflammation, β-Cell Function, Diabetes Management +7

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Stephen C. Bain, Ofri Mosenzon, Rosario Arechavaleta et al. · Diabetes Obesity and Metabolism · 2018 · 94 citations · Full text

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain

Fernando Gómez‐Peralta, Timothy C. Dunn, Katherine Landuyt et al. · BMJ Open Diabetes Research & Care · 2020 · 92 citations · Full text